Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.
Cardoso F, O'Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, Harbeck N, Telli ML, Cescon DW, Fasching PA, Shao Z, Loirat D, Park YH, Fernandez MG, Rubovszky G, Spring L, Im SA, Hui R, Takano T, André F, Yasojima H, Ding Y, Jia L, Karantza V, Tryfonidis K, Bardia A.
Cardoso F, et al. Among authors: fernandez mg.
Nat Med. 2025 Jan 21. doi: 10.1038/s41591-024-03415-7. Online ahead of print.
Nat Med. 2025.
PMID: 39838117